Quarterly Report I 22/23

September 2022 – November 2022, Diamyd Medical AB (publ), Fiscal year 2022/2023Precision Medicine for Autoimmune Diabetes in Pivotal Phase 3Diamyd Medical’s B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B.Further information is available on https://www.diamyd.com September 1, 2022 – November 30, 2022 · Net result: MSEK -33.0 (-37.8) · Result per share: SEK -0.4 (-0.5) · Cash flow from operating activities: MSEK -27.1 (0) · Cash and short-term investments at November 30, 2022: MSEK 130.9 (240.7). Significant events during the first